In this "Gray Sheet" podcast from the AdvaMed meeting, John Bishop, who is Cepheid's CEO and also chairman of AdvaMedDx, discusses the FDA and reimbursement outlook for molecular tests, and his company's effort to broaden the reach of these traditionally complex diagnostic tools into physicians' offices and other less-sophisticated laboratory environments.
